



(12) Translation of new
European patent specification
After opposition procedure

(11) NO/EP 2358756 B2

NORWAY

(19) NO
(51) Int Cl.

C07K 16/40 (2006.01) A61P 3/06 (2006.01)
A61K 39/00 (2006.01) C07K 16/12 (2006.01)
A61K 39/08 (2006.01) C12N 9/64 (2006.01)
A61K 39/395 (2006.01) G01N 33/569 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2017.05.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.01.11
(45)	Decision of the opposition in EPO	2023.07.26
	Decision of the opposition in NIPO	2023.10.02
(86)	European Application Nr.	09793408.7
(86)	European Filing Date	2009.12.15
(87)	The European Application's Publication Date	2011.08.24
(30)	Priority	2008.12.15, US, 122482 P 2009.03.18, US, 210566 P 2009.04.13, US, 168753 P 2009.06.18, US, 218136 P 2009.10.06, US, 249135 P 2009.11.17, US, 261776 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	AL ; BA ; RS
(73)	Proprietor	Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
(72)	Inventor	SLEEMAN, Mark, W., c/o Monash University Clayton 2 Albert Place Bldg 77 SOBS Clayton, Richmond, Victoria 3121, Australia MARTIN, Joel, H., c/o Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road, Tarrytown New York 10591, USA HUANG, Tammy, T., c/o Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road, Tarrytown New York 10591, USA MACDONALD, Douglas, c/o Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road, Tarrytown New York 10591, USA
(74)	Agent or Attorney	AWA NORWAY AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54) Title **HIGH AFFINITY HUMAN ANTIBODIES TO PCSK9**

(56) References

Cited:

WO-A1-2009/026558

WO-A2-2008/057457

WO-A2-2008/057458

WO-A2-2008/057459

WO-A2-2008/125623

WO-A2-2008/133647

WO-A2-2009/055783

LAGACE THOMAS A ET AL: "Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 116, no. 11, 1 November 2006 (2006-11-01), pages 2995-3005, XP002493243 ISSN: 0021-9738

ALBORN WILLIAM E ET AL: "Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol" CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 53, no. 10, 1 October 2007 (2007-10-01), pages 1814-1819, XP009104836 ISSN: 0009-9147

CHAN JOYCE C Y ET AL: "A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 16 JUN 2009, vol. 106, no. 24, 16 June 2009 (2009-06-16), pages 9820-9825, XP002570200 ISSN: 1091-6490

WINTER G ET AL: "Humanized antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 14, no. 6, 1 June 1993 (1993-06-01), pages 243-246, XP024347425, ISSN: 0167-5699, DOI: 10.1016/0167-5699(93)90039-N [retrieved on 1993-06-01]

BENDIG M M ED - GORDANA VUNJAK-NOVAKOVIC: "HUMANIZATION OF RODENT MONOCLONAL ANTIBODIES BY CDR GRAFTING", METHODS, ACADEMIC PRESS, US, vol. 8, 1 January 1995 (1995-01-01), pages 83-93, XP002944589, ISSN: 1046-2023

Y.G. Ni, et al, "A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake." The Journal of Biological Chemistry 285.17(2010): 12882

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Humant antistoff eller antigen-bindende fragment av et humant antistoff som spesifikt binder humant proprotein konvertasesubtilisin/keksin type 9 (hPCSK9) omfattende en HCVR med SEQ ID NO:90 og en LCVR med SEQ ID NO:
5 92.
2. Antistoff ifølge krav 1, som er et IgG1 eller IgG4.
3. Isolert nukleinsyremolekyl som koder for et antistoff eller antigen-bindende fragment ifølge krav 1 eller krav 2.
4. Ekspresjonsvektor omfattende et nukleinsyremolekyl ifølge krav 3.
- 10 5. Fremgangsmåte for å fremstille et anti-humant PCSK9-antistoff eller antigen-bindende fragment av et antistoff, omfattende trinnene å innføre en ekspresjonsvektor ifølge krav 4 i en isolert vertcelle, dyrke cellen under betingelser som tillater produksjon av antistoffet eller fragmentet derav, og isolere det således fremstilte antistoff eller fragment.
- 15 6. Farmasøytisk sammensetning omfattende et antistoff eller antigen-bindende fragment ifølge krav 1 eller krav 2, og en farmasøytisk akseptabel bærer.
7. Antistoff eller antigen-bindende fragment av et antistoff ifølge krav 1 eller krav 2 for anvendelse for å svekke eller hemme en PCSK9-mediert sykdom eller tilstand i et individ, hvor den PCSK9-medierte sykdom eller tilstand er
20 hyperkolesterolemi.
8. Anvendelse av et antistoff eller antigen-bindende fragment av et antistoff ifølge krav 1 eller krav 2 ved fremstilling av et legemiddel for anvendelse for å svekke eller hemme en PCSK9-mediert sykdom eller tilstand i et individ, hvor den PCSK9-medierte sykdom eller tilstand er hyperkolesterolemi.